Monitor the Nasdaq hearing outcome and the stock's post-split price action. If the stock fails to hold above $1.00 for 10 consecutive days, delisting becomes likely, which could further depress the stock. The clinical pipeline offers no near-term revenue catalyst.
Price Chart
Executive Summary
Genprex filed a Certificate of Amendment for a 1:22 reverse stock split effective July 16, 2026, to regain compliance with Nasdaq's $1.00 minimum bid price requirement after receiving a delisting notice on June 10, 2026. The company has requested a hearing before a Nasdaq Hearings Panel, but there is no guarantee the split will restore compliance or that the stock will remain listed. The filing also includes routine clinical trial updates and an investor presentation.
Key Facts
- 1:22 reverse stock split effective July 16, 2026; pre-split shares outstanding: 11,108,577; post-split estimated ~504,936 shares
- Nasdaq delisting notice received June 10, 2026 for failure to maintain $1.00 minimum bid price; company requested a hearing before a Nasdaq Hearings Panel
- Reverse split is intended to regain compliance, but the company warns it may not increase the stock price proportionately or maintain compliance
- Clinical trial updates: Acclaim-1 Phase 2a expansion enrolling; Acclaim-3 Phase 2 expansion targeting enrollment of first 25 patients by end of 2026 with interim analysis in H1 2027
- Market cap ~$6M; pre-revenue biotech with no approved products
Financial Impact
No financial figures reported; reverse split reduces share count but does not change market cap; delisting risk could impair capital access
Risk Factors
- Nasdaq delisting if reverse split fails to maintain $1.00 bid price for 10 consecutive days
- Reverse split may not proportionally increase stock price; liquidity could decline with fewer shares outstanding
- Pre-revenue biotech with no approved products; cash burn and dilution risk remain high
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-023480 |
| Exhibit: ex_983257.htm | 0001437749-26-023480 |
| Document: 0001437749-26-023480-index-headers.html | 0001437749-26-023480 |
| Document: 0001437749-26-023480-index.html | 0001437749-26-023480 |
| Document: 0001437749-26-023480.txt | 0001437749-26-023480 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 5d ago | 8-K | $2.05 | awaiting T+60 | — | $1.81 (−11.71%) |
Aug 18, 2026 9w ago | 8-K | $3.95 | awaiting T+60 | — | $1.81 (−54.18%) |
Aug 3, 2026 12w ago | 8-K | $4.75 | awaiting T+60 | — | $1.81 (−61.89%) |
Jul 14, 2026 14w ago | 8-K | $0.4632 $0.1191 | ▲ +74.29% | ▲ +77.67% | $1.81 (−290.76%) |
Jun 22, 2026 18w ago | 8-K | $0.5501 $0.1550 | ▼ −71.82% | ▼ −73.12% | $1.81 (+229.03%) |
May 26, 2026 21w ago | 8-K | $16.98 $3.99 | ▼ −76.51% | ▼ −79.23% | $1.81 (−89.34%) |
May 14, 2026 23w ago | 8-K | $18.94 $4.19 | ▼ −77.88% | ▼ −81.47% | $1.81 (−90.44%) |
Apr 28, 2026 25w ago | 8-K | $20.35 $7.49 | ▼ −63.19% | ▼ −67.18% | $1.81 (−91.11%) |
Apr 21, 2026 26w ago | 8-K | $23.98 $7.67 | ▼ −68.02% | ▼ −73.86% | $1.81 (−92.45%) |
Mar 18, 2026 31w ago | 8-K | $2.01 $0.6540 | ▼ −67.46% | ▼ −78.99% | $1.81 (−9.95%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers